Current Pharmacology Reports最新文献_第5页

Imatinib Analogs in Chronic Myeloid Leukemia: a Systematic Qualitative Review 伊马替尼类似物治疗慢性髓性白血病:一项系统定性评价

Current Pharmacology Reports Pub Date : 2023-04-10 DOI: 10.1007/s40495-023-00316-0

Kavita Sangwan, Suman Khurana, Pratibha Dhakla

引用次数: 0

Mechanism-Based Physiological Effects of Piperine: A Review 胡椒碱基于机制的生理效应研究进展

Current Pharmacology Reports Pub Date : 2023-03-14 DOI: 10.1007/s40495-023-00314-2

Shafkeen Siddiqui, M. Khushtar, A. Zafar, S. M. Hasan, M. Arshad, M. Ahmad, Mohd. Kashif, Mohammad Mujahid

引用次数: 1

Drug Discovery from Natural Sources 从自然资源中发现药物

Current Pharmacology Reports Pub Date : 2023-02-27 DOI: 10.1007/s40495-023-00313-3

David Newman

引用次数: 3

Novel and Green Method for Synthesis of Fluorescent ZnS Quantum Dots from Latex of Plant Calotropis gigantea 以巨茶甘露为原料合成荧光ZnS量子点的绿色新方法

Current Pharmacology Reports Pub Date : 2023-01-13 DOI: 10.1007/s40495-022-00311-x

Gurlovleen Kaur, Ranjeeta Bhari, Kuldeep Kumar

引用次数: 0

Utilization of Drug Decision Support Strategies Including Drug Characteristics to Reduce the Risk of Iatrogenesis in Advanced Age 利用包括药物特征在内的药物决策支持策略降低老年人用药风险

Current Pharmacology Reports Pub Date : 2023-01-09 DOI: 10.1007/s40495-022-00310-y

Savanna San Filippo, Marshall Yuan, E. Gu, Sabiyah Siddiqui, Savan Patel

引用次数: 0

CD4 + Count: a Variable to Be Considered to Prioritize COVID-19 Vaccination in PLHIV. CD4 +计数:在PLHIV中优先考虑COVID-19疫苗接种的一个变量

Current Pharmacology Reports Pub Date : 2023-01-01 DOI: 10.1007/s40495-023-00312-4

Vakada Lakshmi Mounika, V Udaya Kumar, Sameer Dhingra, V Ravichandiran, Krishna Pandey, Vipan Kumar Parihar, Krishna Murti

{"title":"CD4 + Count: a Variable to Be Considered to Prioritize COVID-19 Vaccination in PLHIV.","authors":"Vakada Lakshmi Mounika, V Udaya Kumar, Sameer Dhingra, V Ravichandiran, Krishna Pandey, Vipan Kumar Parihar, Krishna Murti","doi":"10.1007/s40495-023-00312-4","DOIUrl":"https://doi.org/10.1007/s40495-023-00312-4","url":null,"abstract":"The outbreak of the COVID-19 propagates, pressurizing the healthcare system by emphasizing and worsening the inequities. While many vaccines have shown excellent efficacy in protecting the general public from the COVID-19 infection, the efficacy of these vaccines for people living with HIV (PLHIV), especially those having a different range of CD4 + T-cell, has yet to be thoroughly investigated. Few studies have uncovered the escalated infection and death rates due to the COVID-19 infection in individuals with low CD4 + T-cells. Additionally, PLHIV has a low CD4 + count; furthermore, specific CD4 + T cells for coronavirus have a vigorous Th1 role and are related to the protective antibody responses. Follicular helper T cells (TFH) are vulnerable to HIV and virus-specific CD4 & CD8 T-cells which are essential for viral infection clearance and defective immune responses which further contributes to the development of illness. The specific CD8 & CD4 + T-cell reaction to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was identified in almost all COVID-19 recovered individuals, which is related to the size of antibodies of immunoglobulin G. It has previously been demonstrated that PLHIV has decreased responses to certain vaccines and that these responses are reliant on CD4 + T-cell levels. COVID-19 vaccines will likely have a lower response or limited effect, in PLHIV having low CD4 + T-cells.","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 2","pages":"90-97"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9082646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Emergence of Mpox: Epidemiology and Current Therapeutic Options. m痘的出现:流行病学和当前的治疗选择。

Current Pharmacology Reports Pub Date : 2023-01-01 DOI: 10.1007/s40495-023-00318-y

Samriddhi Ranjan, Kanupriya Vashishth, Katrin Sak, Hardeep Singh Tuli

{"title":"The Emergence of Mpox: Epidemiology and Current Therapeutic Options.","authors":"Samriddhi Ranjan, Kanupriya Vashishth, Katrin Sak, Hardeep Singh Tuli","doi":"10.1007/s40495-023-00318-y","DOIUrl":"https://doi.org/10.1007/s40495-023-00318-y","url":null,"abstract":"The world recently witnessed the emergence of new epidemic outbreaks like COVID-19 and mpox. The 2022 outbreak of mpox amid COVID-19 presents an intricate situation and requires strategies to combat the status quo. Some of the challenges to controlling an epidemic include present knowledge of the disease, available treatment options, appropriate health infrastructures facilities, current scientific methods, operations concepts, availability of technical staff, financial funds, and lastly international policies to control an epidemic state. These insufficiencies often hinder the control of disease spread and jeopardize the health of countless people. Also, disease outbreaks often put a huge burden on the developing economies. These countries are the worst affected and are immensely dependent on assistance provided from the larger economies to control such outbreaks. The first case of mpox was reported in the 1970s and several outbreaks were detected thereafter in the endemic areas eventually leading to the recent outbreak. Approximately, more than 80,000 individuals were infected, and 110 countries were affected by this outbreak. Yet, no definite vaccines and drugs are available to date. The lack of human clinical trials affected thousands of individuals in availing definite disease management. This paper focuses on the epidemiology of mpox, scientific concepts, and treatment options including future treatment modalities for mpox.","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 3","pages":"144-153"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9520486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Molecular Mechanisms of Bismuth-containing Drugs Against Helicobacter pylori: a Further Update 含铋药物抗幽门螺杆菌分子机制研究进展

Current Pharmacology Reports Pub Date : 2022-12-31 DOI: 10.1007/s40495-022-00305-9

Jiahui Liu, Xinhang Li, Yulin Zhu, R. Ge

引用次数: 4

Promising Molecular Targets and Novel Therapeutic Approaches in Neuroblastoma 神经母细胞瘤有前途的分子靶点和新的治疗方法

Current Pharmacology Reports Pub Date : 2022-12-31 DOI: 10.1007/s40495-022-00306-8

Xu Yang, Jixia Li, Ji-gang Yang

引用次数: 0

Interaction Between Natural Products and Gut Microbiota 天然产物与肠道菌群的相互作用

Current Pharmacology Reports Pub Date : 2022-12-31 DOI: 10.1007/s40495-022-00309-5

D. Ağagündüz, Ö. Cemali, E. Çelik

引用次数: 1